108 results about "Invasive pituitary adenoma" patented technology

The invention provides application of specific gene mutation in molecular diagnosis and targeted therapy of pituitary adenoma detection. Specifically, the invention provides a type of specific gene mutations in patients suffering from pituitary adenoma. The experimental result proves that the patients suffering from pituitary adenoma can be diagnosed by detecting the gene mutations.

A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

The invention discloses a use of a biological marker detection reagent in preparing a kit for detecting the invasiveness of pituitary adenomas, and a kit and a biological marker combination for detecting the invasiveness of pituitary adenomas. The invasiveness of pituitary adenomas of a patient can be detected by detecting an expression level of a biological marker, so that the grade malignancy of the pituitary adenomas can be known, and an effective basis can be provided for knowing the prognosis of the pituitary adenomas and instructing the clinical diagnosis and treatment.

The invention discloses a molecular marker for diagnosis and treatment of pituitary adenoma. Pituitary adenoma is a common intracranial benign tumor and can induce endocrine symptoms as well as intracranial hypertension and change of vision and view. Experiments prove that the expression of PAEP gene in the pituitary adenoma tissue is up-regulated, and the expression of the PAEP gene can inhibit the proliferation of pituitary adenoma cells and promote the apoptosis of the pituitary adenoma cells. The invention provides a new molecular means for the diagnosis and treatment of pituitary adenoma.

The invention provides the use of a reagent for detecting the expression level of a protein marker in preparing a product for detecting radiotherapy resistance of a pituitary adenoma, as well as a kit and protein marker combination for detecting the radiotherapy resistance of a pituitary adenoma. The present invention can detect the sensitivity of the treated object to radiotherapy of pituitary adenoma by detecting the expression level of protein markers, and analyze whether there is radiotherapy resistance, thereby providing an effective basis for predicting the effect of patients receiving radiotherapy and guiding clinical diagnosis and treatment.

The invention discloses a human pituitary adenoma cell line and application thereof, and belongs to the field of tumor biology. The collection number of human pituitary adenoma cell line (HPA1446) is CGMCC NO.12672. The human pituitary adenoma cell line has the advantages that the cell line can be cultured in vitro for a long time, the cell characteristic is not changed, and the cell line is a powerful tool for related research of pituitary adenoma; the cell line is a powerful tool for studying tumor disease and related molecule action mechanisms, preparing tumor related animal experiment models, studying, screening and evaluating tumor treatment medicines/methods/diagnosis reagents, developing tumor medicine targets and tumor biological treatment new techniques, and detecting study of related biological engineering.

The invention belongs to the technical field of biological medicine and relates to a medicine composition for treating pituitary adenoma, application of the medicine composition, a medicine box and a packaging piece. The medicine composition, the medicine box and the packaging piece contain chloroquine/hydroxychloroquine which serves as a combined preparation and is used simultaneously, separately or sequentially, and a therapeutically effective amount of dopamine receptor agonist, and the dopamine receptor agonist is cabergoline or bromocriptine. When the medicine composition, the medicine box and the packaging piece are used for treating tumors, the medicine effect which is superior to the medicine effect obtained by separately using the cabergoline can be achieved, and the clinical treatment effect is improved.

The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.

The invention discloses a novel acromegaly screening system and a screening method thereof. The system comprises a pituitary adenoma intelligent health management platform, a hand feature database andan artificial intelligence early screening system; the pituitary adenoma intelligent health management platform is used for collecting hand photos of a to-be-tested person. the pituitary adenoma intelligent health management platform stores the collected hand photos in a hand feature database; the artificial intelligence early screening system comprises a convolutional neural network; the convolutional neural network carries out artificial intelligence deep learning on the hand photos in the hand feature database, so that a deep learning model is established, operation is carried out, and repeated verification and correction and data classification are carried out; and the artificial intelligence early screening system performs artificial intelligence background measurement and calculation on the hand photos, then outputs screening data, and preliminarily determines whether the patient is acromegaly patient or not according to the screening data; The novel acromegaly screening systemis low in cost and high in efficiency, replaces hematology/nuclear magnetic resonance examination and the like, and effectively reduces investment of manpower and material resources for screening.

The invention discloses use of brusatol and analogues thereof or pharmaceutically acceptable salts thereof in preparing medicines for treating pituitary adenoma. Different from a classic approach of promoting tumor cell apoptosis by DRD2 dependence of a dopamine receptor agonist, the brusatol and analogues thereof achieve inhibition effects of medicine on pituitary adenoma such as prolactinoma, clinical non-functional pituitary adenoma and growth hormone adenoma by promoting cells to generate ROS to induce cell apoptosis.

The invention relates to the technical field of medical appliances, and discloses a basis cranii repairing device for resection of pituitary adenoma via sphenoid sinus. The device comprises a first plug disc and a lumbar support formed on the first side of the first plug disc, wherein the first plug disc and the lumbar support have metal reticular structures; the second side surface of the first plug disc is coated with a first flexible blocking layer; the first flexible blocking layer is larger than the first plug disc, and the periphery of the first flexible blocking layer extends out of the edge of the first plug disc. The basis cranii repairing device can be used for effectively repairing the skull defect after repairing operation due to the first plug disc and the first flexible blocking layer, cerebrospinal fluid leakage is prevented, and infection rate is reduced.

The invention discloses an application of an estrogen receptor related receptor gamma (ESRRG) variant transcript in auxiliary diagnosis of pituitary adenoma, especially in auxiliary diagnosis of prolactin pituitary adenoma. By detecting whether the ESRRG transcript has an abnormal transcript or not and developing and applying the diagnostic kit, the pituitary adenoma, especially prolactin pituitary adenoma, can be more conveniently and easily diagnosed, so that a patient can know the disease risk in the early stage of the disease, a simple and effective auxiliary means is provided for drug screening, drug effect evaluation and targeted therapy of prolactin pituitary adenoma, especially prolactin pituitary adenoma.

The invention provides a nonfunctional pituitary adenoma detection device and application thereof. The device is used for carrying out Massarray SNP parting detection on a mononucleotide polymorphic site rs2981582 of a sample to be detected; the site has significant correlation with the attack of the nonfunctional pituitary adenoma; different genetic models of the site can provide certain basis for diagnosis of the nonfunctional pituitary adenoma and have higher clinical values. Through the nonfunctional pituitary adenoma detection device and the application thereof, a simple and reliable diagnosis method is provided for early diagnosis of patients with nonfunctional pituitary adenoma.

The invention discloses application of circRNA-PTN to pituitary adenoma biomarkers, and particularly relates to the technical field of purposes of natural ribonucleotide. The length of the circRNA-PTNis 452bp; the circRNA-PTN is positioned on 137254974 to 137251230 on a 7th chromosome of a human body; PTN is a covering gene of the circRNA; the circRNA-PTN is formed by fourth, fifth and sixth exons of the PTN through trans-splicing; the quantity of the circRNA-PTN from a pituitary adenoma tissue sample of an object is detected; the lower-quantity circRNA-PTN has high pituitary adenoma invasiveness and is relevant to the bad prognosis possibility increase of the object. The purpose of the circRNA-PTN is provided. The circRNA-PTN has the application prospects of becoming the pituitary adenoma biomarkers.

The invention discloses a gene combination for distinguishing non-invasive and invasive non-functional pituitary adenomas. The gene combination consists of the following genes of INSM1, Jun, JunB, RHOU, RHOB, EZR, LLGL2, SNX33, SPIRE2, MLF1, HSPA2, CDKN1A, ERN1, NR2F2, GAS2, CDK6, SFRP1, EMILIN2, CD9 and SEMA7A. By detecting the expression level of the gene combination, the non-invasive and invasive non-functional pituitary adenomas can be distinguished.

The invention relates to a pituitary adenoma operation patch and a producing method thereof. The patch is filled at a skull base bone defect opening of pituitary adenoma operation, and the edge shape of the patch is matched with the edge shape of the bone defect opening; the patch is a piece made of a PCL-TCP material. The producing method of the patch comprises the following steps: performing data processing by virtue of computer image processing and three-dimensional substantive design software, and performing 3D printing to produce the patch. The pituitary adenoma operation patch has the beneficial effects that the advantages of a computer image processing technique is utilized, the pituitary adenoma operation patch is produced by combining the novel material PCL-TCP with the 3D printing technique, and then the bone defect is repaired. The pituitary adenoma operation patch is high in producing speed, high in structural property, excellent in biological property, high in precision and high in repair tightness, the surgery cost can be reduced, the operation time is shortened, the postoperative complications are reduced, the operative wound is alleviated, postoperative recovery is promoted, and the benefits of patients are maintained.

Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The invention provides application of USP48 gene mutation in ACTH type pituitary adenoma molecular diagnosis and particularly provides a specific gene mutation in body of a patient with ACTH type pituitary adenoma, i.e. USP48 gene mutation. Experiment results show that, through detection on the USP48 gene mutation, the patient with the ACTH type pituitary adenoma can be diagnosed, and a diagnosisbasis is provided for subsequent specific and targeted treatment. The invention also provides application of such mutation genes as a pituitary adenoma therapeutic target.